BMS Korea, AstraZeneca Korea expand diabetes alliance

Published: 2013-04-03 06:58:00

Updated: 2013-04-03 06:58:00

BMS Korea and AstraZeneca Korea received the Korean marketing rights of Byetta (exenatide) injection and Bydureon (exenatide extended-release for injectable suspension) from Lilly Korea as of April 1, following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myer...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK